Hims & Hers Health Narrows 2026 Guidance After Q3 Results

Hims & Hers Health reported Q3 results below expectations on Nov. 9, reducing its 2026 revenue forecast to $3.13B-$3.15B and adjusting EBITDA guidance. Shares fell 14.92% to $22.12 by Nov. 10.

Original reporting
Published Nov 10, 2026, 11:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 2:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hims & Hers Health Narrows 2026 Guidance After Q3 Results — source image
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss and guidance reduction triggered a sharp sell‑off, suggesting near‑term downside risk.

02

Market read

The news directly impacts HIMS stock and may influence sentiment toward the broader telehealth sector.

03

What to watch

Potential cost‑saving initiatives or upcoming product launches that could offset the revenue shortfall.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Hims & Hers Health is a publicly traded telehealth provider that has been expanding its consumer health platform.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Hims & Hers Health reported Q3 results that missed expectations and narrowed its 2026 revenue guidance to $3.13‑$3.15 B, causing the stock to fall 14.9%.

Expected impact

downward pressure as investors reprice lower 2026 outlook

Evidence & confidence

The company lowered full‑year revenue guidance and its shares dropped nearly 15% on the news, indicating a strong negative reaction.

Market effects

Telehealth sector may face broader valuation pressure as guidance cuts raise concerns about demand and cost structure.

U.S. market sentiment could be slightly dampened, especially among health‑tech and digital‑health stocks.

Limited to U.S. investors; no immediate global macro impact.

Counterpoint

If the guidance cut reflects a temporary slowdown and the company can improve margins, the stock may be oversold.

Key entities

  • Hims & Hers Health

    Telehealth provider that reported Q3 results and lowered 2026 guidance.

Related articles

$HIMSHigh

Five US states join FTC suit against Hims & Hers over privacy practices

Five US states joined the FTC's lawsuit against Hims & Hers, alleging deceptive privacy practices, including sharing sensitive health data with Meta and Snap. The case also claims misleading billing and cancellation practices. Hims & Hers plans to defend against the claims. The company recently cut its full-year core profit forecast due to higher costs. (199 characters)

$HIMSMed

Hims & Hers (HIMS) Stock Price Faces Q3 Results Margin Reckoning

Hims & Hers Health (HIMS) reported a Q3 gross margin of 57% and reduced full-year adjusted EBITDA guidance to $257M-$277M, below analyst expectations. The stock fell 17% post-earnings, reflecting concerns about margin erosion and slower profitability growth. Analysts warn that reinvestment in AI and lower prices may delay earnings growth.

$HIMSHigh

US FTC files amended complaint against Hims&Hers

The FTC filed an amended complaint against Hims & Hers, alleging it shared sensitive health data with Meta and Snap, misled consumers about privacy, and engaged in deceptive subscription practices. The case includes Arizona, Florida, Nebraska, Ohio, and Wisconsin as co-plaintiffs. Hims & Hers shares fell 14.73% after the initial filing in July 2026, and a class-action lawsuit was filed.

$HIMSMed

Five states join the FTC's privacy and billing lawsuit against Hims & Hers

Five states joined the FTC's lawsuit against Hims & Hers, alleging privacy violations and deceptive billing practices. The FTC claims Hims shared health data with third parties and hid cancellation terms. Hims plans to defend itself, calling the new claims 'follow-on' allegations. The company recently reported a 49% revenue increase to $890 million but cut its 2026 profit outlook.

$HIMSMed

Five more states join FTC privacy complaint against Hims & Hers Health

The FTC and five additional states (Arizona, Florida, Nebraska, Ohio, Wisconsin) joined a complaint against Hims & Hers Health (HIMS), alleging the company shared patient health data with third-party advertisers. Utah and California were previously involved in the complaint. The case highlights potential privacy violations and regulatory risks for HIMS.